Metformin - Versionsgeschichte

Penarc: ] schluss

2013-02-19T12:22:35Z

] schluss

← Nächstältere Version		Version vom 19. Februar 2013, 12:22 Uhr
Zeile 7:		Zeile 7:
	\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''		\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''
	\| align="left" width="800" \|		\| align="left" width="800" \|
	<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref><ref>[http://www.scielo.br/pdf/ramb/v57n1/v57n1a15.pdf		<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref><ref>[http://www.scielo.br/pdf/ramb/v57n1/v57n1a15.pdf Vitamin B12 in metformin-treated diabetic patients: a cross-sectional study in Brazil Rev Assoc Bras 57:46-49.(2011)]</ref><ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102322/pdf/TOBEJ-5-1.pdf Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus Open biomed Eng. J. 5 1-7]</ref>
	[[Vitamin B12]] in metformin-treated diabetic patients: a cross-sectional study in Brazil]
	Rev Assoc Bras 57:46-49.(2011)</ref><ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102322/pdf/TOBEJ-5-1.pdf Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus] Open biomed Eng. J. 5 1-7</ref>

	\|-		\|-

Mutter Erde: Schützte „Metformin“ ([edit=autoconfirmed] (unbeschränkt) [move=autoconfirmed] (unbeschränkt))

2011-12-08T15:00:02Z

Schützte „Metformin“ ([edit=autoconfirmed] (unbeschränkt) [move=autoconfirmed] (unbeschränkt))

← Nächstältere Version	Version vom 8. Dezember 2011, 15:00 Uhr
(kein Unterschied)

Mutter Erde: Änderungen von AkylaXlwMu (Diskussion) rückgängig gemacht und letzte Version von Penarc wiederhergestellt

2011-12-08T14:59:35Z

Änderungen von AkylaXlwMu (Diskussion) rückgängig gemacht und letzte Version von Penarc wiederhergestellt

← Nächstältere Version		Version vom 8. Dezember 2011, 14:59 Uhr
Zeile 1:		Zeile 1:
	[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]		[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]
			[[Datei:Metformin-from-xtal-3D-balls.png\|thumb]]
	{\| class="wikitable" \|		{\| class="wikitable" \|
	\| bgcolor="#dfdfdf" \| '''Siehe auch'''		\| bgcolor="#dfdfdf" \| '''Siehe auch'''
Zeile 6:		Zeile 7:
	\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''		\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''
	\| align="left" width="800" \|		\| align="left" width="800" \|
	<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref>		<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref><ref>[http://www.scielo.br/pdf/ramb/v57n1/v57n1a15.pdf
			[[Vitamin B12]] in metformin-treated diabetic patients: a cross-sectional study in Brazil]
			Rev Assoc Bras 57:46-49.(2011)</ref><ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102322/pdf/TOBEJ-5-1.pdf Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus] Open biomed Eng. J. 5 1-7</ref>

	\|-		\|-
	\| bgcolor="#dfdfdf" \| '''Wichtige Übersichtsartikel'''		\| bgcolor="#dfdfdf" \| '''Wichtige Übersichtsartikel'''
Zeile 50:		Zeile 54:
	<references />		<references />

			{{commonscat\|Metformin}}

	{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}		{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}
			[[Kategorie:Arzneistoff]]

AkylaXlwMu am 8. Dezember 2011 um 14:58 Uhr

2011-12-08T14:58:29Z

← Nächstältere Version		Version vom 8. Dezember 2011, 14:58 Uhr
Zeile 1:		Zeile 1:
	[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]		[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]
	~~[[Datei:Metformin-from-xtal-3D-balls.png\|thumb]]~~
	{\| class="wikitable" \|		{\| class="wikitable" \|
	\| bgcolor="#dfdfdf" \| '''Siehe auch'''		\| bgcolor="#dfdfdf" \| '''Siehe auch'''
Zeile 7:		Zeile 6:
	\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''		\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''
	\| align="left" width="800" \|		\| align="left" width="800" \|
	<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref>~~<ref>[http://www.scielo.br/pdf/ramb/v57n1/v57n1a15.pdf~~		<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref>
	~~[[Vitamin B12]] in metformin-treated diabetic patients: a cross-sectional study in Brazil]~~
	Rev Assoc Bras 57:46-49.(2011)</ref><ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102322/pdf/TOBEJ-5-1.pdf Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus] Open biomed Eng. J. 5 1-7</ref>

	\|-		\|-
	\| bgcolor="#dfdfdf" \| '''Wichtige Übersichtsartikel'''		\| bgcolor="#dfdfdf" \| '''Wichtige Übersichtsartikel'''
Zeile 54:		Zeile 50:
	<references />		<references />

	~~{{commonscat\|Metformin}}~~

	{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}		{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}
	~~[[Kategorie:Arzneistoff]]~~

Penarc: Datei:Metformin-from-xtal-3D-balls.png

2011-06-11T00:15:03Z

Datei:Metformin-from-xtal-3D-balls.png

← Nächstältere Version		Version vom 11. Juni 2011, 00:15 Uhr
Zeile 1:		Zeile 1:
	[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]		[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]
	[[Datei:Metformin ~~010 Generika~~.~~jpg~~\|thumb]]		[[Datei:Metformin-from-xtal-3D-balls.png\|thumb]]
	{\| class="wikitable" \|		{\| class="wikitable" \|
	\| bgcolor="#dfdfdf" \| '''Siehe auch'''		\| bgcolor="#dfdfdf" \| '''Siehe auch'''

Penarc: 20.rfz

2011-06-11T00:06:17Z

20.rfz

← Nächstältere Version		Version vom 11. Juni 2011, 00:06 Uhr
Zeile 9:		Zeile 9:
	<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref><ref>[http://www.scielo.br/pdf/ramb/v57n1/v57n1a15.pdf		<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref><ref>[http://www.scielo.br/pdf/ramb/v57n1/v57n1a15.pdf
	[[Vitamin B12]] in metformin-treated diabetic patients: a cross-sectional study in Brazil]		[[Vitamin B12]] in metformin-treated diabetic patients: a cross-sectional study in Brazil]
	Rev Assoc Bras 57:46-49.(2011)</ref>		Rev Assoc Bras 57:46-49.(2011)</ref><ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102322/pdf/TOBEJ-5-1.pdf Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus] Open biomed Eng. J. 5 1-7</ref>

	\|-		\|-

Penarc: Rfz 19

2011-03-16T17:03:15Z

Rfz 19

← Nächstältere Version		Version vom 16. März 2011, 17:03 Uhr
Zeile 7:		Zeile 7:
	\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''		\| bgcolor="#dfdfdf" \| '''Freie Übersichtsartikel'''
	\| align="left" width="800" \|		\| align="left" width="800" \|
	<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref>		<ref name="PMID19391221">ACP Journal Club. Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes. Ann Intern Med 150(8):JC4-8 (2009) PMID 19391221 </ref><ref name="PMID12093242">Metformin: an update. Ann Intern Med 137(1):25-33 (2002) PMID 12093242 </ref><ref name="PMID12453950">Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25(12):2133-40 (2002) PMID 12453950 </ref><ref name="PMID10333901">First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22(1):38-44 (1999) PMID 10333901 </ref><ref name="PMID10333900">Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22(1):33-7 (1999) PMID 10333900 </ref><ref name="PMID17296508">Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management. Diabetes Metab 32(6):555-6 (2006) PMID 17296508 </ref><ref name="PMID15671920">Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30(6):509-16 (2004) PMID 15671920 </ref><ref name="PMID14502107">The potential of metformin for diabetes prevention. Diabetes Metab 29(4 Pt 2):6S104-11 (2003) PMID 14502107 </ref><ref name="PMID14502106">Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2):6S95-103 (2003) PMID 14502106 </ref><ref name="PMID14502105">Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88-94 (2003) PMID 14502105 </ref><ref name="PMID14502103">Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 29(4 Pt 2):6S71-6 (2003) PMID 14502103 </ref><ref name="PMID14502102">Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab 29(4 Pt 2):6S62-70 (2003) PMID 14502102 </ref><ref name="PMID14502101">Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 29(4 Pt 2):6S53-61 (2003) PMID 14502101 </ref><ref name="PMID14502100">Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29(4 Pt 2):6S44-52 (2003) PMID 14502100 </ref><ref name="PMID14502099">Improving survival with metformin: the evidence base today. Diabetes Metab 29(4 Pt 2):6S36-43 (2003) PMID 14502099 </ref><ref name="PMID14502098">Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29(4 Pt 2):6S28-35 (2003) PMID 14502098 </ref><ref name="PMID17476355">Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117(5):1226-9 (2007) PMID 17476355 </ref><ref name="PMID12020329">Frequency of inappropriate metformin prescriptions. JAMA 287(19):2504-5 (2002) PMID 12020329 </ref><ref>[http://www.scielo.br/pdf/ramb/v57n1/v57n1a15.pdf
			[[Vitamin B12]] in metformin-treated diabetic patients: a cross-sectional study in Brazil]
			Rev Assoc Bras 57:46-49.(2011)</ref>

	\|-		\|-
	\| bgcolor="#dfdfdf" \| '''Wichtige Übersichtsartikel'''		\| bgcolor="#dfdfdf" \| '''Wichtige Übersichtsartikel'''

Penarc: jpg

2011-03-16T16:45:13Z

jpg

← Nächstältere Version		Version vom 16. März 2011, 16:45 Uhr
Zeile 1:		Zeile 1:
	[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]		[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]
			[[Datei:Metformin 010 Generika.jpg\|thumb]]
	{\| class="wikitable" \|		{\| class="wikitable" \|
	\| bgcolor="#dfdfdf" \| '''Siehe auch'''		\| bgcolor="#dfdfdf" \| '''Siehe auch'''

Penarc: Kat Arzneistoff

2011-03-16T16:33:42Z

Kat Arzneistoff

← Nächstältere Version		Version vom 16. März 2011, 16:33 Uhr
Zeile 53:		Zeile 53:

	{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}		{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}
			[[Kategorie:Arzneistoff]]

Penarc: {{commonscat Metformin}}

2011-03-16T16:29:26Z

← Nächstältere Version		Version vom 16. März 2011, 16:29 Uhr
Zeile 50:		Zeile 50:
	<references />		<references />

			{{commonscat\|Metformin}}

	{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}		{{LinkWP_Miniartikel\|Txt=Metformin\|Link=Metformin}}

← Nächstältere Version		Version vom 11. Juni 2011, 00:15 Uhr
Zeile 1:		Zeile 1:
	[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]		[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]
	[[Datei:Metformin ~~010 Generika~~.~~jpg~~\|thumb]]		[[Datei:Metformin-from-xtal-3D-balls.png\|thumb]]
	{\| class="wikitable" \|		{\| class="wikitable" \|
	\| bgcolor="#dfdfdf" \| '''Siehe auch'''		\| bgcolor="#dfdfdf" \| '''Siehe auch'''

← Nächstältere Version		Version vom 16. März 2011, 16:45 Uhr
Zeile 1:		Zeile 1:
	[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]		[[Datei:pptpdtjpg1.png\|miniatur\|Entstehender Artikel]]
			[[Datei:Metformin 010 Generika.jpg\|thumb]]
	{\| class="wikitable" \|		{\| class="wikitable" \|
	\| bgcolor="#dfdfdf" \| '''Siehe auch'''		\| bgcolor="#dfdfdf" \| '''Siehe auch'''